Beijing Second Pharmaceutical Receives EU cGMP Certification
This article was originally published in PharmAsia News
Executive Summary
Beijing Second Pharmaceutical, Beijing Pharmaceutical Group's pioneer in going overseas, recently received EU cGMP certification after it initiated an international certification application to be a global pharmaceutical competitor. The company-made anti-hypertensive amlodipine tablets will be sold to Europe and the U.S. within the year, marking a breakthrough for the standard of its pharmaceutical formulation. This also represents a milestone for China's pharmaceutical formulation exports. Industry analysts estimate that the country's nearly 6,000 pharmaceutical firms only account for 3 percent of worldwide drug revenues. Oversupply in the domestic market has led to the profit slump, thus going global is a good strategy for local companies. (Click here for more - Chinese Language)